Santarus, Inc. (SNTS) has provided investors with an impressive return over the last year. After having increasing 100% YTD, its 30-day RSI still remains low at only 41.5, which is a good indication that its common stock is no where near being overbought. Investors who have already had the luxury of capitalizing on these returns, may want continue holding, as there is plenty of upside potential to make initiating a position worthwhile for new investors. From an operational standpoint, Santarus is in an excellent position to continue gaining further market share within its niche segment of the bio-pharmaceutical industry. Industry peers are always a competitive threat for this industry in particular, however high barriers to entry surrounding...
Santarus' Impressive Margins, High ROIC, And Low Financial Risk Boost Upside Potential
Sep 23 2013, 07:59 | about: SNTS
BOOKMARKED / READ LATER
Added to your bookmarks on the Seeking Alpha homepage